

REMARKS

Restriction under 35 U.S.C. § 121 has been made. Applicants elect without traverse the invention of Group I, Claim 2 and Claims 1 and 3-7 in part, drawn to a compound of Claim 2 wherein either X or Y is S, classified in class 546, subclass 114.

As requested, Applicants select a species within the elected invention to be examined which is the species named 6-(3,4-difluoro-benzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-[1,3,4]thiadiazolo[3,2-a]pyridine-2-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide. The selected species is found in Claim 7 on page 88, at lines 10-11.

Information Disclosure Statement

Applicants make available to the Patent and Trademark Office an Information Disclosure Statement ("IDS") on form PTO/SB/08A and/or PTO/SB/08B and required copies of the art cited thereon.

Applicants respectfully request that the Examiner consider carefully the complete text of the cited reference(s) in connection with the examination of the above-identified application in accord with 37 CFR §1.104(a).

It is respectfully requested that all cited reference(s) considered by the Examiner be listed in the "References Cited" portion of any patent issuing from the instant application (MPEP § 1302.12).

Conclusion

Applicants respectfully request consideration of the elected invention of the above-recited claims.

The Commissioner is hereby authorized to charge any fees that may be required, or credit any overpayment, to deposit account number 23-0455.

The undersigned would welcome a telephone call from the Examiner to discuss any matters related to this case that the Examiner thinks are amenable to resolution by such discussion.

Respectfully submitted,

Date: May 20, 2004

Claude F. Purchase, Jr.

Claude F. Purchase, Jr.

Reg. No. 47,871

Pfizer Inc.

2800 Plymouth Road

Ann Arbor, MI 48105

Tel. (734) 622-1692

Fax (734) 622-1553